Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P21741

UPID:
MK_HUMAN

ALTERNATIVE NAMES:
Amphiregulin-associated protein; Midgestation and kidney protein; Neurite outgrowth-promoting factor 2; Neurite outgrowth-promoting protein

ALTERNATIVE UPACC:
P21741; Q2LEK4; Q9UCC7

BACKGROUND:
Midkine plays a pivotal role in mediating cellular responses through its interaction with cell-surface receptors, influencing a wide range of processes from inflammatory response to tissue regeneration. It functions by binding to proteoglycan receptors, thereby regulating cell proliferation, differentiation, and migration. This protein's multifaceted role in biological systems makes it an intriguing subject for scientific inquiry.

THERAPEUTIC SIGNIFICANCE:
The exploration of Midkine's functions offers promising avenues for therapeutic development. Given its critical role in inflammation, tissue repair, and cell survival mechanisms, targeting Midkine could lead to innovative treatments for conditions characterized by these pathological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.